Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostatic Neoplasms. Found 208 abstracts

no pagination
Chhatre S, Jefferson A, Cook R, Meeker CR, Kim JH, Hartz KM, Wong YN, Caruso A, Newman DK, Morales KH, Jayadevappa R. Patient-centered recruitment and retention for a randomized controlled study. Trials. 2018 Mar 27;19(1):205.   PMCID: PMC5870194
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-82.   PMCID: PMC5805480
Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Practical radiation oncology. 2018 Jan;8(1):40-7.
Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and health. 2018 Aug;40:e2018040.   PMCID: PMC6232654
Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama. 2018 Mar 06;319(9):896-905.   PMCID: PMC5885899
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080-7.   PMCID: PMC5891129
Mikropoulos C, Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadalo L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer. 2018 Jan;118(2):266-76.   PMCID: PMC5785754
Roach M, Moughan J, Lawton CA, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1504-15.   PMCID: PMC6540797
Woolf SH, Krist AH, Lafata JE, Jones RM, Lehman RR, Hochheimer CJ, Sabo RT, Frosch DL, Zikmund-Fisher BJ, Longo DR. Engaging Patients in Decisions About Cancer Screening: Exploring the Decision Journey Through the Use of a Patient Portal. Am J Prev Med. 2018 Feb;54(2):237-47.
Gore JL, du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson DJ, Karsh L, Lane BR, Franks M, Chen DY, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study. Cancer. 2017 Aug;123(15):2850-9.   PMCID: PMC5573983
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Joshi S, Kutikov A. Editorial Comment. J Urol. 2017 Feb;197(2):383-4.
Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 May;71(5):766-73.
Lawton CA, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun;98(2):296-303.   PMCID: PMC5603177
Lynch SM, Mitra N, Ross M, Newcomb C, Dailey K, Jackson T, Zeigler-Johnson CM, Riethman H, Branas CC, Rebbeck TR. A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness. PLoS One. 2017 Mar;12(3):e0174548.   PMCID: PMC5367705
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr;35(4):125-34.
Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Zajdlewicz L, Hyde MK, Lepore SJ, Gardiner RA, Chambers SK. Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study. Cancer nursing. 2017 Sep;40(5):412-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostatic Neoplasms

Prostatic Neoplasms Male Aged Middle Aged pathology therapeutic use Androgen Antagonists Adult Prostate-Specific Antigen methods Treatment Outcome 80 and over Aged blood mortality Neoplasm Grading therapy Time Factors drug therapy adverse effects Retrospective Studies administration & dosage Neoplasm Metastasis Follow-Up Studies Prostatectomy Adenocarcinoma Combined Modality Therapy radiotherapy statistics & numerical data Kallikreins psychology Multivariate Analysis diagnosis United States Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Neoplasm Staging Radical prostatectomy Early Detection of Cancer Attitudes Health Knowledge-Practice Health Services Accessibility Conformal Radiotherapy Drug Administration Schedule Proportional Hazards Models Brachytherapy secondary Logistic Models Hormonal Antineoplastic Agents Hormone-Dependent Neoplasms Prospective Studies Surveys and Questionnaires Radiotherapy Prognosis Female prevention & control Risk Disease Progression Decision Making Treatment Failure Quality of Life Goserelin Antineoplastic Agents Flutamide Kaplan-Meier Estimate Docetaxel surgery Area Under Curve prostate cancer Tosyl Compounds Residence Characteristics Breast Neoplasms Adjuvant Chemoradiotherapy Dose Fractionation Canada Veterans Salvage Therapy Pharmaceutical Services Insurance Taxoids Tumor Biomarkers Anilides postprostatectomy Patient Dropouts Registries Proto-Oncogene Proteins c-bcl-2 Gleason 9 chemotherapy Randomized Controlled Trials as Topic Intensity-Modulated Radiotherapy genetics Patient Education as Topic Social Support Oral Administration adjuvant therapy Kidney Neoplasms Local treatment Patient Participation statistics & androgen deprivation Mammography Gonadotropin-Releasing Hormone Androgen antagonists docetaxel BRCA2 Protein Germ-Line Mutation Cyclin-Dependent Kinase Inhibitor p16 Gleason 10 Genetic Predisposition to Disease Risk Factors Patient Selection Health Status chemistry Hormones Neoplasm Invasiveness salvage therapy Cytoreductive radical prostatectomy Lymphatic Metastasis Deductibles and Coinsurance radiation Radiation Dose Fractionation Second Primary Neoplasms Medical Assistance Survival Rate Cytoreduction Longitudinal Studies Factual Databases Emotional Adjustment Adjuvant Radiotherapy Lung neoplasms Risk Assessment Surgery in systemic Prostatic neoplasms Poverty Patient Portals Research Subjects Cause of Death prostatectomy Income Severity of Illness Index Prostate Comparative Effectiveness Research analysis Anxiety Progression-Free Survival Tumor Suppressor Protein p53 quality of life Radiosurgery Proto-Oncogene Proteins c-mdm2 Colorectal Neoplasms ROC Curve agonists BRCA1 Protein
Last updated on Friday, December 06, 2019